CompoAtlas

ULTRA SLIM BURNER GELULES

Food supplement declared in France, decision dated 28 October 2025

ULTRA SLIM BURNER GELULES (EAFIT) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).

Brand
EAFIT
Food business operator placing the product on the market
EQUILIBRE ATTITUDE
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Gélule
Daily dose
4 gélules
Directions for use
2 gélules au petit déjeuner et 2 gélules au déjeuner avec un grand verre d'eau
Intended populations
Population générale
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, À prendre en dehors des repas, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Problèmes cardiaques, Sous anticoagulants, Sous traitement pour la thyroïde, Ulcère (estomac ou duodenum), Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
Objectives stated by the manufacturer (these are not authorised claims)
Minceur / Capteur

Declaration 338097, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Camellia sinensis (L.) KuntzeFeuilleExtrait sec aqueux270 mg
Ascophyllum nodosum (L.) Le JolisThalleExtrait sec aqueux200 mg
Vitis vinifera L.PépinExtrait sec hydroalcoolique200 mg
Paullinia cupana KunthGraineExtrait sec aqueux145 mg
Hieracium pilosella L.Parties aériennesExtrait sec aqueux100 mg

Other active ingredients

NamePer day
Caféinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Chlorure de chromeChromepas de limite (données insuffisantes)25 µg
Chlorhydrate de pyridoxineVitamine B612 mg2 mg

Additives

E470b, E464

Other ingredients

maltodextrine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

ID-alG™ est une marque des laboratoires Nexira.Contient de la caféine. (Caféine : 91 mg / 4 gélules).La prise de ce complément alimentaire en dehors des repas, ainsi que la consommationpar les enfants, les adolescents, les femmes enceintes ou allaitantes est déconseillée (thé vert).Ne pas dépasser la dose recommandée. Il est conseillé de consommer ce complémentdans le cadre d’une alimentation variée et équilibrée et d’un mode de vie sain. Tenirhors de portée des jeunes enfants. Déconseillé aux personnes souffrantes de troubles de la thyroïde (iode dans ID-alG™). L'emploi est à éviter pour les personnes suivant un traitement anticoagulant ou prendre l’attache d’un professionnel de santé (fucoïdanes dans ID-alG™).

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : EAFIT

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line